MerTK regulates HCC tumor cell ferroptosis via the ERK/SP1 pathway
(A) Western blot analysis of p-MerTK, MerTK, p-ERK, ERK, p-SP1, SP1, SLC7A11, and β-actin expression in Res1-6, Res1-6-shMerTK, and Res1-6 treated with ERK1/2 inhibitor (HY-126288).
(B) Western blot analysis of p-MerTK, MerTK, p-ERK, ERK, p-SP1, SP1, SLC7A11, and β-actin expression in Hepa1-6, Hepa1-6-OE-MerTK, and Hepa1-6-OE-MerTK treated with ERK1/2 inhibitor.
(C–E) (C) Fluorescence detection of lipid ROS by C11-BODIPY and (D) statistical analysis of relative lipid ROS fluorescence signal in Hepa1-6 tumor cells and (E) in Res1-6 tumor cells.
(F–H) (F) Fluorescence detection of dead cells by SYTOX Green, (G) statistical analysis of percentage dead cells in Hepa1-6 tumor cells and (H) in Res1-6 tumor cells.
All results are shown as mean ± SEM (n = 5). One- or two-way ANOVA was used to analyze the data; ∗∗p < 0.01 and ∗∗∗p < 0.001.